SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCAugust 6, 2026

ORCHARD final data: modest benefit for osimertinib plus gefitinib in EGFR C797X, and no further study advised

Final data from the osimertinib plus gefitinib module of ORCHARD (NCT03944772) have been published in Clinical Cancer Research, and the authors reported that the combination produced only modest clinical benefit in patients whose disease progressed on first-line osimertinib with an acquired EGFR C797X mutation.
Share

In brief

  • The osimertinib plus gefitinib module of the phase II ORCHARD study treated 31 patients with EGFR-mutated advanced NSCLC carrying an EGFR C797X mutation after progression on first-line osimertinib.
  • The confirmed objective response rate was 26%, with a median duration of response of 4.2 months, median progression-free survival of 5.1 months and median overall survival of 19.0 months.
  • The authors concluded that the risk-benefit profile does not support further evaluation of the combination in this population.

Background

Osimertinib is standard first-line treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC), and the disease eventually progresses in most patients who receive it. EGFR C797X is a known resistance mechanism to osimertinib: the substitution affects the cysteine residue that osimertinib binds covalently, which is the rationale that has been proposed for pairing it with a reversible inhibitor such as gefitinib. ORCHARD evaluated resistance mechanisms after first-line osimertinib and the therapies given after progression.

Study design

ORCHARD is a phase II, open-label study in patients with EGFR-mutated advanced NSCLC and progressive disease on first-line osimertinib. In the module reported here, patients with EGFR C797X received osimertinib 80 mg once daily plus gefitinib 250 mg once daily, continued until progressive disease, unacceptable toxicity, or another discontinuation criterion was met. The primary endpoint was objective response rate assessed by the investigator according to RECIST 1.1.

Findings

Thirty-one patients were treated and were evaluable for response and safety at the data cutoff of 10 May 2024. Eight patients had a partial response, for a confirmed objective response rate of 26% (80% CI 16 to 39). The median duration of response was 4.2 months (95% CI 2.8 to 5.5).

By the cutoff, 30 patients (97%) had a progression-free survival event and 19 patients (61%) had died. Median progression-free survival was 5.1 months (95% CI 3.9 to 6.8) and median overall survival was 19.0 months (95% CI 14.6 to 25.0).

Safety

Eleven patients (35%) had grade 3 or higher adverse events. The authors reported that safety was consistent with the known adverse-event profiles of osimertinib and gefitinib given individually, with no new safety signals.

Resistance after the combination

Several resistance mechanisms were identified in patients who progressed on osimertinib plus gefitinib, including EGFR T790M, BRAF and PIK3CA mutations.

What comes next

The authors concluded that osimertinib plus gefitinib demonstrated modest clinical benefit in patients with EGFR C797X identified after progression on first-line osimertinib, and that the risk-benefit profile indicates further evaluation of this regimen in this population is not warranted.

Sources

  1. Clinical Cancer Research. Osimertinib Plus Gefitinib in Patients with EGFR -Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD (2026-07-13). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Xiuning Le and Zofia Piotrowska.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard